Unlearn is the developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies.
Unlearn's platform accelerates drug development by pioneering computational clinical trials.
Unlearn.AI was founded in 2017 by Jonathan Walsh, Aaron Smith, and Charles Fisher. The company is headquartered in San Francisco, California.
Unlearn.AI is the only company creating TwinRCTs™, a randomized trial that uses machine learning and historical data to achieve a higher probability of success with a smaller number of patients.
Unlearn announced a multi-year collaboration with Merck KGaA, Darmstadt, Germany which is using TwinRCTs™ to incorporate prognostic information from digital twins into its randomized controlled trials.
Unlearn’s technology has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics.
Unlearn is backed by Insight Partners, 8VC, DCVC, DCVC Bio, Mubadala Capital Venture, and others. The company raised $50M in a Series B round on Apr 19, 2022. This brings Unlearn's total funding to $69.8M to date.